By Stephanie Murg, Managing Director, G2 Intelligence
Earlier this month, the state of Arizona removed all limits on the kinds of laboratory tests that could be ordered by patients with a bill shepherded into law (it takes effect in July) by Theranos (Palo Alto, Calif.), which is piloting its novel, consumer-focused approach at select Phoenix Walgreens locations. Now Laboratory Corporation of America (Burlington, N.C.) is preparing to bet big on…
Read more...
By Kelly A. Briganti, Editorial Director, G2 Intelligence
Laboratory services are at the center of another False Claims Act settlement—this time in an arrangement involving a dermatology practice and its dermatopathology laboratory. A Georgia-based dermatology practice agreed to pay $3.2 million to settle allegations of Stark Law and False Claims Act violations relating to financial relationships between the entity and its physicians. The government claimed…
Read more...
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies
Many of the genetic changes detected by sequencing tumor tissue are not actually associated with the cancer, but reflect inherited germline mutations that are also present in non-cancer cells of the patient, according to a study published April 15 in Science Translational Medicine. As a result, matched "normal" DNA may need to be tested along with tumor tissue in order to effectively personalize therapy selection, the study…
Read more...
By Christopher P. Young, Editor, G2 Compliance Advisor
In an April 21 award of damages in a patent infringement lawsuit filed by Ameritox and Marshfield Clinic against Millennium Health (MH), formerly Millennium Laboratories, jurors decided that $8,652,760 would adequately compensate the plaintiffs for MH's infringement on one of two patents owned by the plaintiffs. Patents number 7,585,680 and 7,785,895, referred to in court documents as the '680 and '895 patents respectively, covered Ameritox's Rx Guardian CD service, a method of monitoring and reporting drug use that includes comparing an individuals' urine drug test results against data from a patient group that has…
Read more...
By Ron Shinkman, Editor, Laboratory Industry Report
A new study by the Cleveland HeartLab and the personalized medicine firm MDVIP concluded that the former's cardiac inflammation assay could significantly reduce the occurrence of heart attacks and strokes.
Altogether, the use of Cleveland HeartLab's inflammation test cut the risk of heart attack and strokes by 10 percent among a patient population that also received wellness services from MDVIP, in particular regular testing of the their blood cholesterol levels. Although that test has long been considered an indicator for…
Read more...
Save the date! The 33rd annual Lab Institute will be held October 14th-16th in Washington, D.C. This year's theme is The Big Reset: Compete and Win in the Emerging Value-Driven Market. We hope you'll join us as we explore how your organization can survive and thrive in the challenging environment ahead for the laboratory and pathology industry.
Interested in sharing your expertise at this year's Lab Institute? We are accepting speaker proposals through April 30. This is your last chance to answer our call for speakers. To be considered, please complete and return the form on our Speakers page. Submissions are considered on a rolling basis.
|
